• Peter Rossing and Murray Epstein.
• Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Head of Complications Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
• Am. J. Med. 2022 May 1; 135 (5): 576-580.

AbstractChronic kidney disease affects approximately 10% of the population or 800 million people globally, with diabetes being the leading cause. The presence of chronic kidney disease with impaired kidney function or with albuminuria is associated with an increased risk of a progressive loss of renal function and increased risk of cardiovascular disease and excess mortality. Screening for chronic kidney disease is critically important because during the initial stages patients often have no symptoms and because we now have available recently approved multiple interventions that can reduce the high risks dramatically. Screening should be performed with regular measurement of albumin in the urine and creatinine or cystatin C in blood for estimation of kidney function. Regretfully recent data indicates that screening for albuminuria is conducted in only 20%-50% of people at risk depending on the setting. Clinicians need to perform regular screening and concomitant management of risk factors. Recent therapeutic options must be implemented to improve outcomes. Finally, a reduction in albuminuria after initiation of intervention constitutes a treatment target because it indicates improved prognosis.Copyright © 2022 Elsevier Inc. All rights reserved.

18 keywords...

hide…